TBET Stock Overview

A specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. More details

TBET fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Latest financial reports are more than a year old

High level of non-cash earnings

Does not have a meaningful market cap ($14)

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

Tibet Pharmaceuticals, Inc. Competitors

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Juva Life

OTCPK:JUVA.F

US$164.0

BZAM

OTCPK:BZAM.F

US$270.0

Price History & Performance

Summary of share price highs, lows and changes for Tibet Pharmaceuticals
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	0%
3 Year Change	-99.00%
5 Year Change	-99.00%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	TBET	US Pharmaceuticals	US Market
7D	0%	-1.7%	-2.6%
1Y	0%	3.2%	24.5%

Return vs Industry: TBET underperformed the US Pharmaceuticals industry which returned 3.2% over the past year.

Return vs Market: TBET underperformed the US Market which returned 24.5% over the past year.

Price Volatility

Is TBET's price volatile compared to industry and market?
TBET volatility
TBET Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: TBET's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine TBET's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2009	n/a	Hong Yu	n/a

Tibet Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Tibetan medicines. The company, through its operational entity, Yunnan Shangri-La Tibetan Pharmaceutical Group Limited (YSTP), develops products in China for promoting health in human respiratory, digestive, urinary, and reproductive systems. Its commercialized products include 25 Ingredients Mandrake Pill, which is used to regulate menses to treat endometritis, pelvic inflammations, and women’s anemia; 15 Ingredients Gentiana Pill to treat bronchitis, emphysema, asthma, and hoarseness; 28 Ingredients Pinang Pill for treating cold waist hip pain, pus hematuria, and testis swelling; 18 Ingredients Chebulic (Myrobalan) Frusemide Pill for the treatment of kidney problems, lumbar and kidney pain, frequent urination, turbid urine, diabetes, and spermatorrhea; and Pomegranate Nichirin Pill to treat indigestion, back and leg pain, frequent urination, foot edema, impotence, and nocturnal emission.

Tibet Pharmaceuticals, Inc. Fundamentals Summary

How do Tibet Pharmaceuticals's earnings and revenue compare to its market cap?
TBET fundamental statistics
Market cap	US$14.00
Earnings (TTM)	US$10.82m
Revenue (TTM)	US$34.05m

0.0x

P/E Ratio

0.0x

P/S Ratio

Is TBET overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TBET income statement (TTM)
Revenue	US$34.05m
Cost of Revenue	US$19.89m
Gross Profit	US$14.17m
Other Expenses	US$3.34m
Earnings	US$10.82m

Last Reported Earnings

Sep 30, 2011

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did TBET perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 19:37
End of Day Share Price	2024/12/30 00:00
Earnings	2011/09/30
Annual Earnings	2010/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tibet Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution